Biomarker Analysis in Clinical Trials with R: Chapman & Hall/CRC Biostatistics Series
Autor Nusrat Rabbeeen Limba Engleză Hardback – apr 2020
Biomarker Analysis in Clinical Trials with R offers practical guidance to statisticians in the pharmaceutical industry on how to incorporate biomarker data analysis in clinical trial studies. The book discusses the appropriate statistical methods for evaluating pharmacodynamic, predictive and surrogate biomarkers for delivering increased value in the drug development process. The topic of combining multiple biomarkers to predict drug response using machine learning is covered. Featuring copious reproducible code and examples in R, the book helps students, researchers and biostatisticians get started in tackling the hard problems of designing and analyzing trials with biomarkers.
Features:
- Analysis of pharmacodynamic biomarkers for lending evidence target modulation.
- Design and analysis of trials with a predictive biomarker.
- Framework for analyzing surrogate biomarkers.
- Methods for combining multiple biomarkers to predict treatment response.
- Offers a biomarker statistical analysis plan.
- R code, data and models are given for each part: including regression models for survival and longitudinal data, as well as statistical learning models, such as graphical models and penalized regression models.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 256.76 lei 43-57 zile | |
CRC Press – 13 dec 2021 | 256.76 lei 43-57 zile | |
Hardback (1) | 655.90 lei 43-57 zile | |
CRC Press – apr 2020 | 655.90 lei 43-57 zile |
Din seria Chapman & Hall/CRC Biostatistics Series
- 22% Preț: 448.53 lei
- 18% Preț: 570.52 lei
- 26% Preț: 680.32 lei
- 26% Preț: 624.69 lei
- 18% Preț: 547.45 lei
- 25% Preț: 773.58 lei
- 26% Preț: 850.48 lei
- 13% Preț: 337.80 lei
- 26% Preț: 625.08 lei
- 18% Preț: 868.11 lei
- 25% Preț: 497.35 lei
- 26% Preț: 552.42 lei
- 26% Preț: 870.09 lei
- 25% Preț: 487.07 lei
- 26% Preț: 623.46 lei
- 26% Preț: 523.78 lei
- 26% Preț: 768.72 lei
- 26% Preț: 495.73 lei
- 22% Preț: 357.66 lei
- 26% Preț: 484.23 lei
- 25% Preț: 564.57 lei
- 26% Preț: 625.08 lei
- 26% Preț: 763.06 lei
- 23% Preț: 426.66 lei
- 8% Preț: 564.25 lei
- 26% Preț: 598.23 lei
- 25% Preț: 771.94 lei
- 25% Preț: 498.96 lei
- 25% Preț: 1214.28 lei
- 26% Preț: 623.05 lei
- 26% Preț: 820.87 lei
- 25% Preț: 554.37 lei
- 26% Preț: 622.23 lei
- 26% Preț: 878.64 lei
- 26% Preț: 882.44 lei
- 25% Preț: 557.13 lei
- 22% Preț: 361.01 lei
- 26% Preț: 524.19 lei
- 26% Preț: 594.17 lei
- 25% Preț: 528.26 lei
- 26% Preț: 521.35 lei
- 26% Preț: 495.33 lei
- 26% Preț: 678.84 lei
- 25% Preț: 774.77 lei
- 22% Preț: 478.75 lei
- 26% Preț: 623.05 lei
- 26% Preț: 625.63 lei
- 25% Preț: 685.51 lei
Preț: 655.90 lei
Preț vechi: 801.31 lei
-18% Nou
Puncte Express: 984
Preț estimativ în valută:
125.54€ • 130.84$ • 104.50£
125.54€ • 130.84$ • 104.50£
Carte tipărită la comandă
Livrare economică 06-20 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781138368835
ISBN-10: 1138368830
Pagini: 228
Ilustrații: 38
Dimensiuni: 156 x 234 x 20 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series
ISBN-10: 1138368830
Pagini: 228
Ilustrații: 38
Dimensiuni: 156 x 234 x 20 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series
Cuprins
Section I Pharmacodynamic Biomarkers 1. Introduction 2. Toxicology Studies 3. Bioequivalence Studies 4. Cross-Sectional Profile of Pharmacodynamics Biomarkers 5. Timecourse Profile of Pharmacodynamics Biomarkers 6. Evaluating Multiple Biomarkers Section II Predictive Biomarkers 7. Introduction 8. Operational Characteristics of Proof-of-Concept Trials with Biomarker-Positive and -Negative Subgroups 9. A Framework for Testing Biomarker Subgroups in Confirmatory Trials 10. Cutoff Determination of Continuous Predictive Biomarker for a Biomarker–Treatment Interaction 11. Cutoff Determination of Continuous Predictive Biomarker Using Group Sequential Methodology 12. Adaptive Threshold Design 13. Adaptive Seamless Design (ASD) Section III Surrogate Endpoints 14. Introduction 15. Requirement # 1: Trial Level – Correlation Between Hazard Ratios in Progression-Free Survival and Overall Survival Across Trials 16. Requirement # 2: Individual Level – Assess the Correlation Between the Surrogate and True Endpoints After Adjusting for Treatment (R2 indiv) 17. Examining the Proportion of Treatment Effect in AIDS Clinical Trials 18. Concluding Remarks Section IV Combining Multiple Biomarkers 19. Introduction 20. Regression-Based Models 21. Tree-Based Models 22. Cluster Analysis 23. Graphical Models Section V Biomarker Statistical Analysis Plan
Notă biografică
Nusrat Rabbee is a biostatistician and data scientist at Rabbee & Associates, where she creates innovative solutions to help companies accelerate drug and diagnostic development for patients. Her research interest lies in the intersection of data science and personalized medicine. She has extensive experience in bioinformatics, clinical statistics and high-dimensional data analyses. She has co-discovered the RLMM algorithm for genotyping Affymetrix SNP chips and co-invented a high-dimensional molecular signature for cancer. She has spent over 17 years in the pharmaceutical and diagnostics industry focusing on biomarker development. She has taught statistics at UC Berkeley for 4 years.
Recenzii
I can imagine applied statisticians having a hardcover version on their desks near their computer, in a somewhat overused condition, referring to this every now and then for the implementation of the described methods in practice. Goal achieved in such a case.
- Christos T. Nakas, International Society for Clinical Biostatistics, 71, 2021
- Christos T. Nakas, International Society for Clinical Biostatistics, 71, 2021
Descriere
The book offers practical guidance on how to incorporate biomarker data analysis in clinical trial studies. The book discusses the appropriate statistical methods for evaluating pharmacodynamic, predictive and surrogate biomarkers for delivering increased value in the drug development process.